SUPPLEMENTARY METHODS

Generation of GAr Modified rtTA2 S -M2
EBNA-1 derived GAr of 8 and 30 amino acid residues and the full length GAr were inserted in the 5' end of the rtTA2 S -M2 gene. To generate the GAr8 equivalent to that described by Shapiro et al. [20] the following oligonucleotides were annealed and ligated to the vectors pUHrT62-1 (encoding rtTA2 S -M2) [49] digested with Eco RI and Xba I: For: AATTCACC ATG TCT AGA GGA GCA GGT GCT GGA GGT GCA GGT A and Rev: CTAGT ACC TGC ACC TCC AGC ACC TGC TCC TCT AGA CAT GGT G. The GAr30 was generated by annealing the following overlapping oligonucleotides and ligating them to the same digested vectors: For 1: AATTC ACC ATG TCT AGA GCT GGA GCA GGC GGT GGA GCA GGT GCT GGA GGT GCA G; Rev1 TCC ACC TGC ACC TCC AGC ACC TGC TCC ACC GCC TGC TCC AGC TCT AGA CAT GGT G; For 2: GT GGA GCA GGC GGT GCA GGA GCA GGT GGT GCA GGT GCT GGA GGT GGA GCA GGT A and Rev 2: C TAGT ACC TGC TCC ACC TCC AGC ACC TGC ACC ACC TGC TCC TGC ACC GCC TGC. A fragment from EBNA-1 consisting of the first 421 amino acids containing the full length GAr (located between aa 90 and 328) was amplified by PCR using the following primer pair: For TCG GAA TTC ACC ATG TCT AGA GAG GGG CCA GGT ACA and Rev GG ACT AGT GCC ACC TTC TTG GTG GTA from the plasmid pCEP4 (Invitrogen Ltd., Paisley, UK). The PCR product was digested with Eco RI and Spe I, purified and cloned into the same expression vectors again linearised with Eco RI and Xba I.
Cloning of Tags for Immunoprecipitation
For the purpose of pulse chase experiments a Flag tag was inserted in the carboxy terminal end of the rtTA2 S -M2 molecules using the oligonucleotides For: CCGGGGGTACCGACTACAAGGACGACGATGACAAGGGTACCTAAG and Rev: GATCCTTAGGTACCCTTGTCATCGTCGTCCTTGTAGTAGGTACCC annealed and cloned into encoding plasmid pUHrT62-1 cut with Xma I and Bam HI. All vectors were confirmed by sequencing (GeneService, Source BioScience UK Ltd., Nottingham, UK) and are depicted in Fig. (1) .
Preparation of Cell Lysates
Plasmid DNA (20 g) was transfected into 293T cells by calcium phosphate precipitation as previously described in the main text of the manuscript. Seventy-two hours after the transfection cells were washed with cold PBS and lysed in RIPA buffer containing protease inhibitor cocktail and sodium orthovanadate. Cells were pelleted by centrifugation (4000 rpm/5 min) were washed with PBS and then lysed in RIPA buffer containing a protease inhibitor cocktail. Protein concentration of the lysates were determined using the Pierce® BCA protein assay kit (Thermo Fisher Scientific Inc.).
Western Blots
Lysates or precipitated proteins were prepared in Laemmli sample buffer and run on SDS-PAGE electrophoresis gels [47] and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham International Plc, UK) by electroblotting. Membranes were probed with primary antibodies to tetR (mAb was a mixture of clones 7.1 and 13.1 from Roche Ltd).and secondary antibody HRP conjugated F(ab') 2 goat anti-mouse IgG (Santa Cruz Inc; CA, USA). Finally, blots were incubated with ECL reagents (Thermo Fisher Scientific Inc.) for 1 minute and then wrapped in Sarogold ®PRO (Thermo Fisher Scientific Inc.) before exposure to photographic film to visualise detected bands.
Dual Luciferase Assay
To determine whether the GAr modifications altered the function of rtTA2 S -M2, 1.25 x 10 5 293T cells per well were plated in a 12-well plate and were transfected with 1 μg of modified or unmodified rtTA2 S -M2 encoding plasmid, 1 μg of pGTL [50] and 0.1 μg of pRL-CMV. Twenty-four hours after transfection, cells were treated with Dox at a concentration of 1 μg/ml. After 48 hours of Dox treatment cells were lysed in passive lysis buffer and luciferase activities measured using the dual-luciferase reporter assay system.
Pulse Chase
Twenty-four hours after transfection of 293T cells with plasmid DNA (10 g) cells were washed with methionine-and cysteine-free medium and incubated with labelling medium (methionine-and cysteine-free medium (Cambrex Bio Science Verviers S.p.r.l.), dialysed 10% fetal bovine serum, penicillin-streptomycin) containing 0.19-.02 mCi/ml RedivueTM PRO-MIX L-( 35 S) in vitro cell labelling mix (GE Healthcare, Buckinghamshire, UK) overnight at 37°C. Labelled cells were then washed and chased with cold medium (DMEM with excess methionine and cysteine) for 0 to 48 hours. At different time points, cells were lysed in RIPA buffer containing protease inhibitor cocktail set III (Calbiochem-Novabiochem (UK) Ltd, Nottingham, UK) and protein concentrations were determined using the Pierce® BCA protein assay kit (Thermo Fisher Scientific Inc.). Four hundred micrograms of cell lysate were precleared with Protein G sepharose Fast Flow before immunoprecipitation with monoclonal anti-FLAG and Protein-G sepharose 4 Fast Flow (GE Healthcare, Uppsala, Sweden). Immunoprecipitated proteins were then separated on a 12% SDS-polyacrylamide gel which was then fixed with a solution containing 10% methanol and 7% acetic acid; the signal was enhanced by bathing the fixed gel in 1M sodium salicylate. The gel was then dried and exposed to a film. Band density on scanned films was then quantitated using TotalLab Quant software (BioSystematica, Tavistock, Devon UK). Fig. (S2) . Generation, detection and properties of GAr modified rtTA2S-M2. (A) schematic representation of the constructs generated and used. In all constructs the ubiquitous CMV promoter (black) was used to drive expression of unmodified or amino modified GAr fusions (white box) of rtTA2S-M2 (striped box). The grey box indicates additional amino sequence from EBNA-1. The same vectors were also prepared with a Flag tag at the carboxy terminal of the transactivator. (B) Detection of GAr-modified proteins on western blots. Plasmids encoding full length, 30aa and 8aa GAr modified versions of rtTA2S-M2 were transiently expressed in 293T cells and expressed proteins were detected in cell lysates by western blotting using anti-tetR. Samples run on the gel were untransfected (U), wild-type molecules (wt), and GAr modified. Both wt and GAr-modified versions of rtTA2S-M2 were detected with anti-tetR monoclonal antibodies which confirm the proteins were of the predicted size. (C) Effect of GAr modifications on function of the tetracycline rtTA2S-M2. The readout of activity in transfected 293T cells was luciferase expressed from the Ptet in the plasmid pGTL which was included in all transfections at a 1:1 ratio with pGTL. (p 0.005). Modification of rtTA-2SM2 by all GAr sequences caused significant changes in activity. In the absence of Dox, basal luciferase expression from pGTL was significantly increased, whilst activities in the induced state were comparable to wt rtTA2SM2 with the exception of the GAr421 version which gave a significantly higher gene induction. (D) Length of GAr sequences differentially modulates t1/2 of rtTA-2SM2 in vitro. 293T cells were transiently transfected with 10 μg of the relevant plasmid DNA and grown in labelling media overnight before washing and chasing for upto 48 hours. Lysates were prepared at the relevant time-points and immunoprecipitated with antibodies to the carboxy terminal tag. Samples were then run on a polyacrylamide gel which was dried before exposure to photographic film which were scanned and the density of bands measured using TotalLab software and results used to determine t1/2 by exponential regression. The t1/2 for wt rtTA2S-M2 was 9.03 hrs, interestingly, addition of the 8 aa GAr decreased the t1/2 to 5.10 hrs whilst the GAr30 domain increased stability of rtTA2S-M2 to 13.91 hrs. Unfortunately we were unable to immunoprecipitate rtTA2S-M2 modified with the full length GAr so we could not determine effects on the t1/2 of this molecule. Fig. (S3) . Kinetics of luciferase expression is not altered by GAr domains but is prolonged by promoter and miR detargeting. Bioluminescent images of mice expressing GAr modified luciferase from pcLuc+/GAr30/-NeoR and pcLuc+/GAr/-NeoR (a). Images of mice in which luciferase expression was detargeted with both the muscle specific promoter and through the use of miR 142-3p target sequences from c5-12Luc+/4T/-NeoR are shown in (b). Fig. (S4) . Bioluminescent images using detargeted forms of GAr30 modified luciferase. Images were collected from mice administered the plasmids pcLuc+/GAr30/4T/-NeoR (a), c5-12Luc+/GAr30/-NeoR (b) and c5-12Luc+/GAr30/4T/-NeoR (c). Fig. (S5) . Luciferase full length GAr is more immunogenic than unmodified luciferase regardless of expression strategy. De-targeted constitutive expression of luciferase full length GAr with miR 142-3p target sequences (a), or expression from the muscle specific promoter c5-12 (b), or combined de-targeting with the muscle specific promoter (c) always results in a more rapid decline in luciferase activity compared with constitutively expressed unmodified luciferase molecule from pcLuc+/-NeoR. Significant differences from pcLuc+ of p 0.005 and p 0.05 are indicated by and respectively. Fig. (S6) . T cell stimulation in relation to light emission over the course of the experiment. T cell stimulation was assessed in cells obtained from 2 mice in each group, light emission for those mice as AUC is plotted in A. IL-2 release following stimulation with ConA or recombinant firefly luciferase as well as basal release are plotted in B. In C, IL-2 production in response to Luc stimulation is divided by light emission in order to examine the relationship between the two. Mean values are shown for the same two mice in each histogram.
